Solventum Corporation Common Stock (SOLV)
Healthcare › Surgical & Medical Instruments & Apparatus
Price History
Feb 9, 2026 — May 24, 2026Investment Snapshot
- Trading 3% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 5/9 — moderate financial health
- Strong ROE of 30.3% with 18.1% net margin
Solventum Corporation Common Stock (SOLV) is a Healthcare company operating in Surgical & Medical Instruments & Apparatus, listed on the NYSE , with a market capitalisation of $13.3 billion . Key value metrics: P/E ratio 8.8, P/B ratio 2.68, Piotroski F-Score 5 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 3 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Solventum Corporation Common Stock — Fundamental Analysis Summary
Solventum Corporation Common Stock (SOLV) is currently trading 3% above its Graham Number of $74.93, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries a low trailing P/E ratio of 8.8x.
On financial health, SOLV shows a moderate Piotroski F-Score of 5/9, and strong return on equity of 30.3% (sector average: -20.6%), and elevated leverage with a debt-to-equity ratio of 1.02.
StockPik's composite Value Score for SOLV is 100/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
SOLV reports a solid gross margin of 54.2% (sector average: 40.1%) and a strong operating margin of 25.6%.
SOLV shows revenue growing at 1% year-over-year, with earnings growing at 225%.